Receptors, Purinergic P2Y12

"Receptors, Purinergic P2Y12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A subclass of purinergic P2Y receptors that have a preference for ADP binding and are coupled to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI. The P2Y12 purinergic receptors are found in PLATELETS where they play an important role regulating PLATELET ACTIVATION.

Descriptor ID	D058925
MeSH Number(s)	D12.776.543.750.695.700.720.500.300 D12.776.543.750.720.700.720.750.300
Concept/Terms	Receptors, Purinergic P2Y12 Receptors, Purinergic P2Y12 P2Y12 Receptors, Purinergic Purinergic P2Y12 Receptors Purinergic Receptor P2Y, G-Protein Coupled, 12 Purinoceptor P2Y12 P2Y12, Purinoceptor P2Y12 Purinoceptors Purinoceptors, P2Y12 P2Y(ADP) Receptor P2Y(T) Receptor P2Y12 Purinoceptor Purinoceptor, P2Y12 Purinoceptor P2T P2T, Purinoceptor Purinergic Receptor P2Y12 P2Y12, Purinergic Receptor P2T Purinoceptor Purinoceptor, P2T

Below are MeSH descriptors whose meaning is more general than "Receptors, Purinergic P2Y12".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, G-Protein-Coupled [D12.776.543.750.695]
Receptors, Purinergic [D12.776.543.750.695.700]
Receptors, Purinergic P2 [D12.776.543.750.695.700.720]
Receptors, Purinergic P2Y [D12.776.543.750.695.700.720.500]
Receptors, Purinergic P2Y12 [D12.776.543.750.695.700.720.500.300]
Receptors, Neurotransmitter [D12.776.543.750.720]
Receptors, Purinergic [D12.776.543.750.720.700]
Receptors, Purinergic P2 [D12.776.543.750.720.700.720]
Receptors, Purinergic P2Y [D12.776.543.750.720.700.720.750]
Receptors, Purinergic P2Y12 [D12.776.543.750.720.700.720.750.300]

Below are MeSH descriptors whose meaning is related to "Receptors, Purinergic P2Y12".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Purinergic P2Y12".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Purinergic P2Y12" by people in this website by year, and whether "Receptors, Purinergic P2Y12" was a major or minor topic of these publications.

Bar chart showing 25 publications over 17 distinct years, with a maximum of 3 publications in 2006 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2004	0	1	1
2005	0	1	1
2006	0	3	3
2010	0	1	1
2011	0	2	2
2012	0	1	1
2013	0	1	1
2014	1	2	3
2015	1	0	1
2016	0	1	1
2017	0	2	2
2018	1	1	2
2019	0	1	1
2020	0	1	1
2022	2	0	2
2025	0	1	1

Below are the most recent publications written about "Receptors, Purinergic P2Y12" by people in Profiles.

Fu Z, Ganesana M, Hwang P, Tan X, Kinkaid MM, Sun YY, Bian E, Weybright A, Chen HR, Sol-Church K, Eyo UB, Pridans C, Quintana FJ, Robson SC, Kumar P, Venton BJ, Schaefer A, Kuan CY. Microglia modulate the cerebrovascular reactivity through ectonucleotidase CD39. Nat Commun. 2025 Jan 22; 16(1):956.

View in: PubMed
Dangelmaier C, Mauri B, Patel A, Kunapuli SP, Kostyak JC. D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function. Int J Mol Sci. 2022 Sep 29; 23(19).

View in: PubMed
Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, Ruf B, Brown Z, Heinrich B, Zhang Q, Rosato U, Wang S, Cui L, Berzofsky JA, Kleiner DE, Bosco DB, Wu LJ, Lai CW, Rotman Y, Xie C, Korangy F, Greten TF. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022 09 12; 40(9):986-998.e5.

View in: PubMed
Elmadany N, Logiacco F, Buonfiglioli A, Haage VC, Wright-Jin EC, Schattenberg A, Papawassiliou RM, Kettenmann H, Semtner M, Gutmann DH. Neurofibromatosis 1 - Mutant microglia exhibit sexually-dimorphic cyclic AMP-dependent purinergic defects. Neurobiol Dis. 2020 10; 144:105030.

View in: PubMed
Nagalla S, Sarode R. Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy. Transfus Med Rev. 2019 04; 33(2):92-97.

View in: PubMed
Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray PF. The protease-activated receptor?4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor?4 desensitization, and is blocked by non-competitive P2Y12 inhibition. J Thromb Haemost. 2018 12; 16(12):2501-2514.

View in: PubMed
Tourdot BE, Stoveken H, Trumbo D, Yeung J, Kanthi Y, Edelstein LC, Bray PF, Tall GG, Holinstat M. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. Arterioscler Thromb Vasc Biol. 2018 07; 38(7):1632-1643.

View in: PubMed
Schmidt RA, Morrell CN, Ling FS, Simlote P, Fernandez G, Rich DQ, Adler D, Gervase J, Cameron SJ. The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction. Transl Res. 2018 05; 195:1-12.

View in: PubMed
Valle-Giler EP, Atallah E, Tjoumakaris S, Rosenwasser RH, Jabbour P. Transcirculation Pipeline embolization device deployment: a rescue technique. Neurosurg Focus. 2017 Jun; 42(6):E13.

View in: PubMed
Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, Jabbour P. P2Y12 Reaction Units: Effect on Hemorrhagic and Thromboembolic Complications in Patients With Cerebral Aneurysms Treated With the Pipeline Embolization Device. Neurosurgery. 2016 Jan; 78(1):27-33.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement